Awkward 发表于 2025-3-21 17:27:44

书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影响因子(影响力)<br>        http://impactfactor.cn/if/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影响因子(影响力)学科排名<br>        http://impactfactor.cn/ifr/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia网络公开度<br>        http://impactfactor.cn/at/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia网络公开度学科排名<br>        http://impactfactor.cn/atr/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引频次<br>        http://impactfactor.cn/tc/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引频次学科排名<br>        http://impactfactor.cn/tcr/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用<br>        http://impactfactor.cn/ii/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用学科排名<br>        http://impactfactor.cn/iir/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia读者反馈<br>        http://impactfactor.cn/5y/?ISSN=BK0665209<br><br>        <br><br>书目名称New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia读者反馈学科排名<br>        http://impactfactor.cn/5yr/?ISSN=BK0665209<br><br>        <br><br>

使激动 发表于 2025-3-21 20:52:19

http://reply.papertrans.cn/67/6653/665209/665209_2.png

Debate 发表于 2025-3-22 00:41:41

http://reply.papertrans.cn/67/6653/665209/665209_3.png

调整校对 发表于 2025-3-22 07:42:53

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute or 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m. twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had

极大的痛苦 发表于 2025-3-22 12:13:43

http://reply.papertrans.cn/67/6653/665209/665209_5.png

使成波状 发表于 2025-3-22 13:22:44

http://reply.papertrans.cn/67/6653/665209/665209_6.png

FRAUD 发表于 2025-3-22 20:01:07

http://reply.papertrans.cn/67/6653/665209/665209_7.png

约会 发表于 2025-3-22 23:41:36

http://reply.papertrans.cn/67/6653/665209/665209_8.png

有恶臭 发表于 2025-3-23 04:16:21

http://reply.papertrans.cn/67/6653/665209/665209_9.png

Flagging 发表于 2025-3-23 07:54:00

http://reply.papertrans.cn/67/6653/665209/665209_10.png
页: [1] 2 3 4
查看完整版本: Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia; W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V